Literature DB >> 6130069

Notes on buspirone's mechanisms of action.

S Garattini, S Caccia, T Mennini.   

Abstract

Buspirone is a novel psychotropic drug with clear anxiolytic activity in man. There are a number of neurochemical differences between buspirone and both neuroleptics and benzodiazepines. Moreover, buspirone is extensively metabolized, and several metabolites are present in the brain together with the parent compound. One of these, 1-PP, is present in the brain at higher concentrations than the parent drug, particularly when the drug is given orally. On the basis of the reported experimental data, it can be postulated that buspirone's anticonflict activity in rats may be mediated, at least partially, through 1-PP, without involving any effect on the dopaminergic system. The possibility that buspirone and 1-PP may mimic the action of benzodiazepine on some sites in the complex benzodiazepine-GABA receptors is discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6130069

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  8 in total

Review 1.  Active drug metabolites. An overview of their relevance in clinical pharmacokinetics.

Authors:  S Garattini
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

2.  Quantitative autoradiographic distribution and pharmacological characterization of (3H)buspirone binding to sections from rat, bovine and marmoset brain.

Authors:  G Brüning; P Kaulen; U Schneider; H G Baumgarten
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

3.  Evidence that central 5-hydroxytryptaminergic neurones are involved in the anxiolytic activity of buspirone.

Authors:  M Carli; C Prontera; R Samanin
Journal:  Br J Pharmacol       Date:  1989-04       Impact factor: 8.739

4.  A Retrospective Chart Review of Buspirone for the Treatment of Anxiety in Psychiatrically Referred Youth with High-Functioning Autism Spectrum Disorder.

Authors:  Tolga Atilla Ceranoglu; Janet Wozniak; Ronna Fried; Maribel Galdo; Barbora Hoskova; Melissa DeLeon Fong; Joseph Biederman; Gagan Joshi
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-11-16       Impact factor: 2.576

5.  Buspirone pharmacokinetics in patients with cirrhosis.

Authors:  K Dalhoff; H E Poulsen; P Garred; M Placchi; R E Gammans; R F Mayol; M Pfeffer
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

6.  Actions of 5-HT1 ligands on excitatory synaptic transmission in the hippocampus of alert rats.

Authors:  J J O'Connor; M J Rowan; R Anwyl
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

7.  Monoaminergic involvement in the pharmacological actions of buspirone.

Authors:  P Skolnick; B A Weissman; M B Youdim
Journal:  Br J Pharmacol       Date:  1985-11       Impact factor: 8.739

Review 8.  Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic.

Authors:  K L Goa; A Ward
Journal:  Drugs       Date:  1986-08       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.